The manuscript published today in NEJM, 'Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine,' provides the final trial analysis, building on an initial interim analysis conducted in January 2021, and the updated analysis announced in March 2021, while additional data from the study was subsequently shared in preprint server medRxiv in May 2021. Today's publication may be accessed here.
"We continue to be very encouraged by data showing high levels of efficacy against even mild disease, and that NVX-CoV2373 offers strong cross-protection against both the B.1.1.7 (Alpha) variant and non-B.1.1.7 (non-Alpha) variant strains which are widely circulating," said Gregory M. Glenn, M.D., President of Research and Development, Novavax. "This publication also reinforces the reassuring safety and efficacy profile shown in studies of our vaccine to-date and underscores the potential for NVX-CoV2373 to play an important role in solving this ongoing global public health crisis."
The randomized, observer-blinded, placebo-controlled study, led by researchers at St George's, University of London and St George's Hospital, London, enrolled more than 15,000 adults at trial sites across the United Kingdom. The research demonstrated that a two-dose regimen of Novavax' COVID-19 vaccine candidate conferred 96.4% protection against non-B.1.1.7 (non-Alpha) variant strains and nearly 90% protection against all strains in circulation at that time. It also demonstrated that initial vaccine side effects were mostly mild and transient, and that no imbalance was seen in more serious adverse events compared with the placebo arm. The study assessed efficacy during a period when the B.1.1.7 (Alpha) variant strain of the virus was emerging and circulating widely in the United Kingdom and is the same variant that is currently widespread in the United States.
"It is quite remarkable how well the vaccine efficacy from our United Kingdom trial matches the results seen in the United States in the recently released PREVENT-19 trial results, giving even more confidence in the potential role of this vaccine in helping to control the pandemic," said Professor Paul Heath, FRCPCH, Vaccine Institute, St George's, University of London and St George's Hospital, London, who is chief investigator of the Novavax United Kingdom trial. "It really highlights the consistent performance of this vaccine in different populations and against a variety of evolving strains."
in 2 weeks it will be approved in UK
- Forums
- ASX - By Stock
- IDT
- IDT offers rival bid to make 100 millions MRNA vaccines
IDT offers rival bid to make 100 millions MRNA vaccines, page-203
-
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IDT (ASX) to my watchlist
(20min delay)
|
|||||
Last
11.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $38.66M |
Open | High | Low | Value | Volume |
11.5¢ | 11.5¢ | 11.0¢ | $16.34K | 145.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 201538 | 10.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
11.0¢ | 30651 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 201538 | 0.105 |
1 | 10000 | 0.100 |
1 | 30000 | 0.099 |
1 | 500000 | 0.098 |
1 | 5500 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.110 | 30651 | 1 |
0.115 | 139865 | 2 |
0.120 | 160964 | 5 |
0.125 | 174981 | 2 |
0.130 | 121156 | 4 |
Last trade - 15.49pm 21/06/2024 (20 minute delay) ? |
Featured News
IDT (ASX) Chart |
The Watchlist
FHE
FRONTIER ENERGY LIMITED
Adam Kiley, CEO
Adam Kiley
CEO
SPONSORED BY The Market Online